Table 2.
Number of immunomodulating therapy sessions. Data are presented as mean (range).
| Therapy | CRC (N = 21) | Pancreatic (N = 14) | CCC (N = 5) | Gastric (N = 5) | Esophageal (N = 4) |
|---|---|---|---|---|---|
| Locoregional mEHT | 16.57 (6–42) | 19.71 (2–47) | 20.20 (13–35) | 25.40 (13–51) | 16.25 (5–44) |
| wIRA hyperthermia | 2.10 (0–19) | 1.93 (0–16) | 2.60 (0–13) | 5.80 (0–17) | 0.25 (0–1) |
| Mild WBH | 3.52 (0–8) | 4.43 (1–8) | 4.80 (3–7) | 5.60 (0–15) | 5.25 (2–10) |
| Moderate WBH | 1.71 (0–15) | 1.79 (0–13) | 2.60 (0–9) | 0.00 (0–0) | 0.25 (0–1) |
| Long duration moderate WBH | 1.00 (0–3) | 2.14 (1–12) | 1.20 (1–2) | 2.60 (1–4) | 1.00 (0–2) |
| Low-dose ipilimumab 1 | 3.57 (0–12) | 3.36 (1–6) | 4.20 (3–6) | 5.00 (3–12) | 6.00 (3–9) |
| Low-dose nivolumab 1 | 4.09 (1–12) | 3.43 (1–7) | 3.60 (2–6) | 6.60 (3–12) | 6.00 (3–9) |
| Interleukin-2 | 3.86 (1–22) | 3.93 (1–14) | 7.40 (1–18) | 2.80 (1–5) | 3.25 (1–6) |
| High-dose vitamin C | 14.81 (2–35) | 16.86 (4–38) | 19.40 (13–36) | 22.20 (13–34) | 15.00 (5–37) |
| Curcumin | 2.00 (0–21) | 1.14 (0–12) | 4.20 (0–15) | 1.00 (0–5) | 2.50 (0–10) |
| Dichloroacetate | 1.71 (0–8) | 3.14 (0–22) | 5.40 (0–12) | 1.60 (0–4) | 4.00 (0–13) |
| Artesunate | 2.05 (0–8) | 0.86 (0–8) | 5.20 (0–11) | 1.00 (0–5) | 0.00 (0–5) |
| Ozone therapy | 0.81 (0–4) | 1.07 (0–7) | 2.40 (0–5) | 0.00 (0–0) | 0.50 (0–2) |
| Interferon-γ | 1.57 (0–13) | 2.64 (0–13) | 3.80 (0–9) | 1.00 (0–5) | 0.00 (0–0) |
| Metronomic chemotherapy | 0.57 (0–11) | 3.93 (0–15) | 1.20 (0–3) | 5.40 (0–18) | 2.75 (1–5) |
1A single patient in the CRC cohort received nivolumab as monotherapy. CCC: cholangiocellular cancer; CRC: colorectal cancer; mEHT: modulated electro-hyperthermia; WBH: whole-body hyperthermia; wIRA: water-filtered infrared-A.